
Vyne Therapeutics (VYNE) Stock Forecast & Price Target
Vyne Therapeutics (VYNE) Analyst Ratings
Bulls say
VYNE Therapeutics is demonstrating promising clinical advancements, particularly with its VYN202 candidate, which has shown significant improvements in patient outcomes related to joint pain and inflammation, indicated by both quantitative data and visual evidence. The company is in a stable financial position, reporting approximately $40 million in cash reserves, enabling it to sustain operations and pursue strategic initiatives moving forward. Additionally, the potential of VYNE's pipeline—especially with FMX114 for atopic dermatitis and ongoing pre-clinical development of BET inhibitor compounds—bolsters a positive long-term outlook for the company's stock.
Bears say
VYNE Therapeutics Inc. has faced significant setbacks following its Phase 2b trial results for vitiligo, which missed primary endpoints, indicating a precarious position for the company. The trial revealed an unusually high vehicle effect and a concerning dropout rate in active treatment arms, leading to VYNE's decision to discontinue the treatment and terminate the trial altogether. Additionally, the company's previous optimistic outlook has shifted, as evidenced by the downgrade from a Buy rating to Neutral, reflecting declining confidence in its growth prospects and product viability.
This aggregate rating is based on analysts' research of Vyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Vyne Therapeutics (VYNE) Analyst Forecast & Price Prediction
Start investing in Vyne Therapeutics (VYNE)
Order type
Buy in
Order amount
Est. shares
0 shares